Lamivudine/raltegravir
Jump to navigation
Jump to search
Combination of | |
---|---|
Lamivudine | Reverse-transcriptase inhibitor |
Raltegravir | Integrase inhibitor |
Clinical data | |
Trade names | Dutrebis |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
KEGG |
Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS.[1] It contains lamivudine and raltegravir. It is taken by mouth.[1] Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes.[1] It was approved for medical use in the United States in 2015.[1][2]
Lamivudine/raltegravir is not available in the United States.[3]
References
- ^ a b c d "Dutrebis (lamivudine and raltegravir)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 10 December 2017.
- ^ "Dutrebis (lamivudine and raltegravir) tablet". U.S. Food and Drug Administration (FDA). 11 April 2016. Retrieved 24 January 2020.
- ^ "Dutrebis (lamivudine and raltegravir) FDA Approval History". Drugs.com. 6 February 2015. Retrieved 24 January 2020.
External links
- "Lamivudine mixture with raltegravir". Drug Information Portal. U.S. National Library of Medicine.
Categories:
- Articles with short description
- Short description is different from Wikidata
- Use dmy dates from January 2020
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Antiretroviral drugs
- Fixed dose combination (antiretroviral)
- HIV/AIDS
- Drugs developed by Merck & Co.
- All stub articles
- Antiinfective agent stubs